New Relic (NEWR) Given Outperform Rating at Wedbush
Wedbush reissued their outperform rating on shares of New Relic (NYSE:NEWR) in a research note released on Wednesday morning, Marketbeat Ratings reports. They currently have a $116.00 price target on the software maker’s stock, down from their...Read More>>>
Insider Buying: Special Opportunities Fund, Inc. (SPE) Insider Purchases $14,470.00 in Stock
Special Opportunities Fund, Inc. (NYSE:SPE) insider Gerald Hellerman bought 1,000 shares of the firm’s stock in a transaction on Thursday, October 11th. The stock was purchased at an average cost of $14.47 per share, with a total value of $14,4...Read More>>>
Ferrari (RACE) Raised to Hold at Societe Generale
Societe Generale upgraded shares of Ferrari (NYSE:RACE) from a sell rating to a hold rating in a research report released on Wednesday morning, Marketbeat reports. Societe Generale currently has $130.00 target price on the stock, up from their previo...Read More>>>
Akoustis Technologies (AKTS) Coverage Initiated at Piper Jaffray Companies
Piper Jaffray Companies started coverage on shares of Akoustis Technologies (NASDAQ:AKTS) in a report published on Wednesday, The Fly reports. The brokerage issued a buy rating and a $10.00 target price on the technology company’s stock.
A numb...Read More>>>
IDEX Co. (IEX) Declares Quarterly Dividend of $0.43
IDEX Co. (NYSE:IEX) announced a quarterly dividend on Thursday, September 13th, RTT News reports. Investors of record on Tuesday, October 16th will be paid a dividend of 0.43 per share by the industrial products company on Wednesday, October 31st. Th...Read More>>>
Marathon Bar Corp. (“Marathon Bar”) was incorporated on October 13, 2011, in the
State of Delaware. On July 24, 2013, Marathon Bar and MBAR Acquisition Corp.
(“Merger Sub”), a wholly owned subsidiary of Marathon Bar, and Lipocine
Operating Inc. (“Lipocine Operating”), a privately held company incorporated in
Delaware, executed an Agreement and Plan of Merger (“Merger Agreement”).
Pursuant to the Merger Agreement, Merger Sub merged with and into Lipocine
Operating and Lipocine Operating was the surviving entity. Additionally,
pursuant to the Merger Agreement, Marathon Bar changed its name to Lipocine Inc.
The Merger is accounted for as a reverse-merger and recapitalization.
We are a specialty pharmaceutical company focused on applying our oral drug
delivery technology for the development of pharmaceutical products in the area
of men’s and women’s health.
Liberty Property Trust (the “Trust”) is a self-administered and self-managed
Maryland real estate investment trust (a “REIT”). Substantially all of the
Trust’s assets are owned directly or indirectly, and substantially all of the
Trust’s operations are conducted directly or indirectly, by its subsidiary,
Liberty Property Limited Partnership, a Pennsylvania limited partnership (the
“Operating Partnership” and, together with the Trust and their consolidated
subsidiaries, the “Company”).
The Company completed its initial public offering in 1994 to continue and expand
the commercial real estate business of Rouse & Associates, a Pennsylvania
general partnership, and certain affiliated entities (collectively, the
“Predecessor”), which was founded in 1972. As of December 31, 2017, the Company
owned and operated 461 industrial and 48 office properties (the “Wholly Owned
Properties in Operation”) totaling 87.3 million square feet.
We are a clinical stage biopharmaceutical company focused on addressing the
large and growing unmet need in diseases caused by transthyretin, or TTR,
amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by
targeting them at their collective source by stabilizing TTR. TTR is a protein
that occurs naturally in the form of a tetramer (a molecular structure
consisting of four identical subunits, or monomers) and performs multiple
beneficial roles, including the transport of essential hormones and vitamins.
Over 25 years of research have shown that ATTR is uniformly driven by
destabilization of the TTR tetramer, stemming from either specific gene
mutations or aging. TTR destabilization drives an irreversible dissociation of
the tetramer into monomers, which subsequently aggregate and deposit
predominantly in the heart and peripheral nervous system, leading to organ
damage, loss of organ function, and eventual death if left untreated.
Sonos was founded with a clear mission–to fill every home with music. This
mission led us to invent wireless multi-room home audio. Sonos transforms the
way people live and interact by restoring the shared experience of music
throughout the home. Our home sound system provides an immersive listening
experience created by our thoughtfully designed speakers and components, our
proprietary software platform and the ability to wirelessly stream the content
our customers love from the services they prefer.
Sonos sits at the intersection of emerging trends driving the future of home
entertainment. The proliferation of streaming services and the rapid adoption of
voice assistants are significantly changing audio consumption habits and how
consumers interact with the internet. As the leading home sound system for
consumers, content partners and developers, Sonos is poised to capitalize on the
large market opportunity created by these dynamics.
Biovail Corporation (“Biovail”) was formed under the Business Corporations Act
(Ontario) on February 18, 2000, as a result of the amalgamation of TXM
Corporation and Biovail Corporation International. Biovail was continued under
the Canada Business Corporations Act (the “CBCA”) effective June 29, 2005. In
connection with the acquisition of Valeant Pharmaceuticals International
(“Valeant”) in September 2010, Biovail was renamed “Valeant Pharmaceuticals
Effective August 9, 2013, we continued from the federal jurisdiction of Canada
to the Province of British Columbia, meaning that we became a company registered
under the laws of the Province of British Columbia as if we had been
incorporated under the laws of the Province of British Columbia.